A better membrane is required
Human Amniotic Membrane (HAM) is a common product used for treating several ocular surface disorders within ophthalmology and other wound healing applications. Despite being the current gold standard, the failure rate of HAM is between 33-44%.
HAM is procured from elective caesarean patients and requires extensive facilities for post-processing, and storage. Furthermore, the use of HAM requires stringent serology tests of donors, a special human tissue license and extensive traceability measures. All of which drives up health care costs and challenges the accessibility of treatment to patients.